OFFIPHARMA

Active Private limited companyfounded 2004active for 22 yearsRue du Gouty 22, 6440 FroidchapelleKBO/BCE: BE 0864.276.532

OFFIPHARMA

Follow Report Compare

Overview

Lifetime

20 annual accounts with figures on one time axis, 22 filings since 2004

Compare with

peak €203,435 (2022)

€124,712▼ 21.1%

lowest -€4,999 (2025)

-€4,999▼ €24,191

peak €266,126 (2024)

€261,127▼ 1.9%

€138,631▲ 8.8%

peak 2.8 FTE (2008)

1.5 FTE▲ 7.1%

Board1 name since 2021

1 director

Documentsfilings and deeds

31-08-202631 days late

2025abbreviated format

Gross margin from €157,990 to €124,712Loss of €4,999

Key points

from the 2025 annual accounts

Turnover

≈ €580,000 estimated

The accounts state no turnover.

Filings

22 annual accounts since 2004

Five of the last ten came late. The 2025 accounts came latest: 31 days after the end of the period.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 12,322 companies had the same profile as OFFIPHARMA has now. Each dot stands for 31 companies, two years later.

90.3%

were still trading

8.5%

stopped another way

0.7%

went bankrupt

Micro
20 years or older
solvency 30% or more
a small loss

Another 0.4% stopped without a precise date, possibly only after those two years.

Test of the method

The method was tested on the 497,331 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group	Expected	Actual
1	0.2%	0.2%
2	0.3%	0.5%
3	0.5%	0.6%
4	0.7%	0.8%
5	0.9%	0.9%
6	1.3%	1.5%
7	1.6%	1.8%
8	1.8%	1.8%
9	2.9%	3.1%
10	5.6%	6.1%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 12,322 companies, not a prediction for OFFIPHARMA. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director, since 13-04-2021

Board & ownership

Recent changes

09-12-2025

Registered in the Peppol Directory Reachable for e-invoices through 0208:0864276532

15-04-2021

Capital decrease of €72,000 to €20,460 Capital from €92,460 to €20,460, 720 shares cancelled · Change of role: , from manager to director · Legal-form conversion: from private limited company (pre-2019) to private limited company · General meeting of 13-04-2021 · Gazette deed

24-03-2004

Incorporation published on 09-04-2004 · Gazette deed

24-03-2004

First establishment Rue du Gouty 22, Froidchapelle

All 32 events

Comparable companies

same main activity, similar in size and age

Company
OFFIPHARMA Froidchapelle	€399,757	€124,712	65.3%	1.5
PHARMACIE DERASSE La Louvière	€387,571	€148,815	26.6%	1.8
PHARMACIE DES PAGODES Genappe	€383,064	€152,066	3.0%	1.6
APOTHEEK MEES NIEUWRODE Holsbeek	€441,980	€134,117	-1.5%	1.9
APOTHEEK HERBRAND Leuven	€417,097	€148,330	65.1%	1.4
APOTHEEK MEES HAACHT STATION Haacht	€499,951	€137,247	37.9%	1.6
Apotheek Van Wambeke Temse	€391,356	€155,445	23.6%	1.7

These companies have the same main activity as OFFIPHARMA: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €383,000 and €500,000, founded between 1999 and 2007.

Official details

Source: KBO

Status: Active since 24-03-2004Normal situation
Activity: Retail sale of pharmaceutical productsNACE 47730
Joint committee: 313Pharmacies and pricing offices · annual accounts 2025
Establishment unit: 2.136.141.6216440 Froidchapelle, since 24-03-2004
Financial year end: 31 December
Peppol: Reachable since 09-12-2025

Company details

Annual accounts 2025

: €124,712▼ 21.1%
: €4,999
: €261,127▼ 1.9%
: €399,757▲ 1.6%
Employeeson 31-12-2025: 3=
Filing: Filed on 31-08-2026

Financials

Insights on OFFIPHARMA

OFFIPHARMA files the abbreviated format. That format states no turnover. The gross margin fell from €155,108 in 2006 to €124,712 in 2025.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette.

Financials

Annual accounts 2025

abbreviated format, filed on 31-08-2026, 31 days late

€124,712

▼ 21.1%

€442

▼ 98.7%

€5,023

▼ 87.8%

-€418

▼ €27,592

65.3%

▼ 2.3 percentage points

2.85

▼ 0.17

The turnover shown is an estimate from the gross margin.

Turnover ≈ €580,000. Estimated: probably between €390,000 and €1.1m.

Money flows

no detail for 2025

Balance sheet

balance sheet total €399,757 on 31-12-2025

What the company ownsHow it is paid for

in euro

Position in the sector

Compare with sector

65.3%

Higher than 78% of 13,234 companies in 2025.

2.85

Higher than 76% of 13,093 companies in 2025.

-1.3%

Higher than 19% of 13,156 companies in 2025.

OFFIPHARMA Middle half of the sector 80% of the sector Abbreviated accounts in retail trade (NACE 47)

Net result: bottom quarter · Equity: middle half · Balance sheet total: bottom quarter · Working capital: middle half · Staff: bottom quarter

Staff

€78,940

Staff costs divided by the average number of full-time equivalents.

people who joined people who left

Filed annual accounts

as filed with the National Bank, click a year to choose it

Line	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006
Balance sheet: assets
`20/58`	399,757	393,514	386,679	358,567	322,171	360,426	438,664	390,068	398,795	372,532	355,713	334,981	304,344	363,991	406,729	436,172	483,098	532,905	550,630	560,536
`21/28`	4,225	8,806	12,307	20,449	11,106	34,349	58,636	31,891	26,623	7,577	9,374	9,397	17,664	48,395	69,222	105,583	141,717	171,036	203,363	210,473
`21`	0	0	0	0	0	0	0	0	0	0	0	0	6,875	34,375	61,875	89,375	116,875	144,375	171,875	199,375
`22/27`	4,225	8,806	12,307	20,449	11,106	34,349	58,636	31,891	26,623	7,577	9,374	9,397	10,789	14,020	7,347	16,208	24,842	26,661	31,488	11,098
`23`	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-
`24`	0	2,440	9,162	16,277	5,500	24,101	43,746	10,614	13,595	3,115	5,952	9,397	10,789	13,800	6,906	15,547	23,961	26,661	31,488	11,098
`26`	4,225	6,365	3,144	4,171	5,606	10,248	14,890	21,276	13,028	4,462	3,422	0	0	220	441	661	881	-	-	-
`29/58`	395,532	384,708	374,373	338,118	311,065	326,077	380,028	358,178	372,173	364,955	346,339	325,584	286,680	315,596	337,507	330,589	341,380	361,869	347,266	350,063
`3`	95,261	86,858	84,139	76,350	80,377	75,539	62,478	65,110	87,225	74,988	79,956	77,445	77,580	85,644	85,834	88,806	76,262	73,985	73,099	65,667
`30/36`	95,261	86,858	84,139	76,350	80,377	75,539	62,478	65,110	87,225	74,988	79,956	77,445	77,580	85,644	85,834	88,806	76,262	73,985	73,099	65,667
`40/41`	112,428	106,427	100,415	93,484	75,618	55,578	62,448	66,416	48,868	107,701	104,262	104,988	101,877	165,340	178,234	165,468	164,763	160,126	145,522	131,780
`40`	89,273	79,329	88,914	85,886	71,792	55,578	52,101	55,167	47,083	56,195	51,918	53,892	46,124	53,821	55,507	48,584	49,560	58,424	48,919	60,984
`41`	23,155	27,098	11,501	7,598	3,826	0	10,347	11,249	1,786	51,506	52,344	51,096	55,753	111,519	122,727	116,884	115,203	101,702	96,603	70,796
`54/58`	184,271	188,824	185,551	167,419	150,631	194,380	255,102	225,975	234,451	180,651	155,905	136,846	104,709	63,236	73,046	71,553	99,928	121,077	122,107	146,805
`490/1`	3,572	2,599	4,268	865	4,439	581	0	677	1,628	1,615	6,216	6,306	2,514	1,377	393	4,762	427	6,682	6,539	5,811
Balance sheet: equity and liabilities
`10/49`	399,757	393,514	386,679	358,567	322,171	360,426	438,664	390,068	398,795	372,532	355,713	334,981	304,344	363,991	406,729	436,172	483,098	532,905	550,630	560,536
`10/15`	261,127	266,126	246,934	222,693	173,999	231,686	233,331	205,140	195,722	181,341	158,731	137,773	33,757	103,792	104,565	105,728	108,582	100,867	96,248	93,840
`10/11`	18,600	18,600	18,600	18,600	18,600	90,600	90,600	90,600	90,600	90,600	90,600	90,600	18,600	18,600	18,600	18,600	18,600	18,600	18,600	18,600
`100`	-	-	-	-	-	-	90,600	90,600	90,600	90,600	90,600	90,600	18,600	18,600	18,600	18,600	18,600	18,600	18,600	18,600
`13`	1,860	1,860	1,860	11,260	25,260	61,925	63,570	63,570	54,170	40,170	3,505	1,860	1,860	1,860	1,860	1,860	1,860	1,860	1,860	1,860
`130/1`	-	-	0	9,400	23,400	61,925	61,710	61,710	52,310	38,310	1,645	-	-	-	-	-	-	-	-	-
`130`	-	-	-	-	-	-	1,860	1,860	1,860	1,860	1,860	1,860	1,860	1,860	1,860	1,860	1,860	1,860	1,860	1,860
`1311`	-	-	0	9,400	23,400	61,925	-	-	-	-	-	-	-	-	-	-	-	-	-	-
`1319`	-	-	-	-	-	-	61,710	61,710	52,310	38,310	1,645	-	-	-	-	-	-	-	-	-
`133`	1,860	1,860	1,860	1,860	1,860	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
`14`	240,667	245,666	226,474	192,833	130,139	79,161	79,161	50,970	50,952	50,571	64,626	45,313	13,297	83,332	84,105	85,268	88,122	80,407	75,788	73,380
`17/49`	138,631	127,389	139,746	135,874	148,172	128,740	205,333	184,929	203,073	191,191	196,982	197,208	270,586	260,199	302,164	330,443	374,515	432,039	454,381	466,696
`17`	-	-	-	-	-	-	-	-	-	-	-	-	0	25,036	50,032	75,028	100,658	133,091	165,206	175,012
`170/4`	-	-	-	-	-	-	-	-	-	-	-	-	0	25,036	50,032	75,028	100,658	133,091	165,206	175,012
`42/48`	138,631	127,389	135,746	135,874	148,172	128,740	205,333	184,929	203,073	191,191	196,982	197,208	269,821	234,109	251,111	243,649	262,263	286,375	277,058	279,531
`42`	-	-	-	-	-	-	-	-	-	-	-	-	0	24,996	24,996	25,630	32,432	32,116	31,813	24,996
`44`	114,321	95,422	101,638	96,152	87,328	62,322	184,874	162,545	176,498	160,551	177,468	166,212	161,274	193,135	202,788	190,208	198,218	218,603	208,816	199,047
`440/4`	114,321	95,422	101,638	96,152	87,328	62,322	184,874	162,545	176,498	160,551	177,468	166,212	161,274	193,135	202,788	190,208	198,218	218,603	208,816	199,047
`45`	24,310	27,192	18,796	20,988	22,519	30,492	18,364	21,336	26,576	29,450	19,351	30,992	31,844	14,085	21,307	18,175	19,184	20,273	18,307	55,465
`450/3`	3,168	2,976	1,511	5,333	10,312	21,998	7,484	8,355	14,043	18,776	11,677	21,538	17,756	3,058	3,689	1,890	2,525	4,102	3,030	36,940
`454/9`	21,142	24,216	17,285	15,655	12,208	8,493	10,880	12,981	12,533	10,674	7,674	9,455	14,088	11,026	17,618	16,285	16,659	16,171	15,278	18,525
`47/48`	-	4,775	15,312	18,733	38,325	35,926	2,095	1,048	-	1,190	163	3	76,703	1,893	2,021	9,635	12,428	15,383	18,121	23
`492/3`	-	0	4,000	-	0	-	-	0	0	-	-	0	765	1,054	1,020	11,766	11,595	12,574	12,117	12,153
Income statement
`70`	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.0m
`76A`	-	-	-	-	-	-	-	-	-	-	-	86	-	698	-	-	-	5,200	-	-
`9900`	124,712	157,990	150,172	203,435	174,176	167,415	154,919	111,982	114,853	122,763	120,483	139,204	135,697	128,030	138,812	132,036	147,461	135,468	144,768	155,108
`60/61`	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	850,804
`62`	118,410	115,734	88,571	104,713	75,522	74,330	73,308	83,657	80,410	73,845	80,153	79,439	76,040	87,831	91,061	89,556	89,832	87,401	80,927	84,216
`630`	4,581	7,981	8,142	8,338	25,368	25,798	30,375	11,522	8,035	5,832	5,104	11,746	31,431	31,490	36,361	36,711	37,921	39,329	39,832	36,716
`631/4`	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,321
`640/8`	1,280	1,079	1,336	1,245	967	2,260	5,984	598	405	513	498	899	894	1,136	1,352	1,357	1,421	1,078	1,932	438
`66A`	-	-	-	-	-	-	-	-	0	70	-	0	10	15	-	-	64	-	10,160	236
`9901`	442	33,196	52,123	89,140	72,318	65,028	45,252	16,205	26,003	42,504	34,729	47,120	27,332	7,573	10,038	4,413	18,287	7,659	22,077	32,417
`75/76B`	41	33	1	30	7	14	30	3	10	62	21	160	39	122	426	193	505	2,453	4,186	2,216
`75`	41	33	1	30	7	14	30	3	10	62	21	160	39	122	426	193	505	2,453	4,186	2,216
`65/66B`	4,994	5,459	5,087	3,814	3,285	4,032	4,321	2,137	1,996	2,277	2,847	3,497	5,185	6,056	7,711	6,882	7,591	8,813	9,992	9,902
`65`	4,994	5,459	5,087	3,814	3,285	4,032	4,321	2,137	1,996	2,277	2,847	3,497	5,185	6,056	7,711	6,882	7,591	8,813	9,992	9,902
`9903`	-4,512	27,770	47,036	85,356	69,040	61,010	40,960	14,070	24,017	40,289	31,903	43,868	22,176	2,323	2,752	-2,276	11,137	6,499	6,112	24,495
`67/77`	488	8,578	13,396	22,662	18,062	15,598	12,769	4,653	9,636	17,678	10,946	11,852	7,511	678	1,498	578	3,421	1,881	3,704	7,952
`9904`	-4,999	19,192	33,641	62,694	50,978	45,412	28,191	9,417	14,381	22,610	20,957	32,016	14,665	1,645	1,255	-2,854	7,716	4,618	2,408	16,543
`9905`	-4,999	19,192	33,641	62,694	50,978	45,412	28,191	9,417	14,381	22,610	20,957	32,016	14,665	1,645	1,255	-2,854	7,716	4,618	2,408	16,543
Appropriation of the result
`9906`	240,667	245,666	226,474	192,833	130,139	124,573	79,161	60,370	64,952	87,236	66,271	45,313	97,997	85,750	86,523	85,268	88,122	80,407	75,788	73,380
`14P`	245,666	226,474	192,833	130,139	79,161	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
`791/2`	-	-	9,400	14,000	36,665	1,645	-	-	-	-	-	-	-	-	-	-	-	-	-	-
`691/2`	-	-	-	-	-	-	-	9,400	14,000	36,665	1,645	-	-	-	-	-	-	-	-	-
`6921`	-	-	-	-	-	-	-	9,400	14,000	36,665	1,645	-	-	-	-	-	-	-	-	-
`694/7`	-	-	9,400	14,000	36,665	47,057	-	-	-	-	-	-	84,700	2,418	2,418	-	-	-	-	-
`694`	-	-	9,400	14,000	36,665	47,057	-	-	-	-	-	-	84,700	2,418	2,418	-	-	-	-	-
Social balance sheet
`9087`	1.5	1.4	1.5	1.4	1.3	1.3	1.3	1.5	1.5	1.4	1.6	1.4	1.5	1.3	2.8	1.8	2.1	2.8	2	2
Hours worked`1013`	2,777	2,711	2,328	2,558	2,549	2,564	2,504	2,924	2,671	2,657	2,934	2,730	2,761	3,385	3,731	3,908	3,918	3,911	3,902	3,886
Document	PDF	PDF	PDF	PDF	PDF	PDF	PDF	PDF	PDF	PDF	PDF	PDF	PDF	PDF	PDF	PDF	PDF	PDF	PDF	PDF

The accounts for 2 older financial years (2004-2005) were filed as documents without figures as data, scans for example.

The notes to these accounts have 7 items, including the statement of assets and debts, the cost breakdown and rights and commitments. You find them in the accounts filed with the NBB.

Source: Annual accounts 2025 at the NBB, filed on 31-08-2026.

Download as CSV

Filings

each dot is a set of accounts, on the day it reached the National Bank

2025 annual accounts filed 31 days after the deadline. Filed on 31 August 2026, deadline 31 July 2026 (7 months after the close on 31 December 2025, Companies Code art. 3:10). Source: NBB, 2026-00501095.

Financial year	Type	Filed	Reference	Document
31-12-2025	abbreviated format	31-08-2026	2026-00501095	PDF
31-12-2024	full format	18-07-2025	2025-00284148	PDF
31-12-2023	full format	19-07-2024	2024-00261306	PDF
31-12-2022	full format	20-07-2023	2023-00254135	PDF
31-12-2021	full format	07-07-2022	2022-20154955	PDF
31-12-2020	full format	12-07-2021	2021-33600130	PDF
31-12-2019	full format	14-08-2020	2020-41000400	PDF
31-12-2018	full format	26-08-2019	2019-49800267	PDF
31-12-2017	full format	24-08-2018	2018-48800158	PDF
31-12-2016	full format	22-08-2017	2017-45100204	PDF
31-12-2015	full format	08-08-2016	2016-40400216	PDF
31-12-2014	full format	20-08-2015	2015-43700213	PDF
31-12-2013	full format	29-08-2014	2014-50100001	PDF
31-12-2012	full format	01-08-2013	2013-38800113	PDF
31-12-2011	full format	19-06-2012	2012-20600588	PDF
31-12-2010	full format	25-07-2011	2011-32900254	PDF
31-12-2009	full format	25-06-2010	2010-22100182	PDF
31-12-2008	full format	22-07-2009	2009-45100194	PDF
31-12-2007	full format	22-07-2008	2008-45700300	PDF
31-12-2006	full format	06-07-2007	2007-36300020	PDF
31-12-2005	full format	06-07-2006	2006-40802925	PDF
31-12-2004	full format	11-07-2005	2005-46004762	PDF

Key figures and ratios

per financial year, computed from the annual accounts

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006
5,023	41,178	60,265	97,477	97,686	90,825	75,627	27,727	34,038	48,336	39,833	58,866	58,763	39,063	46,399	41,123	56,208	46,989	61,909	69,133
-418	27,174	41,783	71,031	76,346	71,210	58,567	20,940	22,416	28,442	26,061	43,762	46,096	33,134	37,615	33,857	45,637	43,948	42,240	53,259
0	4,481	0	17,680	2,126	6,059	57,120	16,790	27,080	4,035	5,081	3,478	700	13,663	0	576	8,602	7,003	32,722	399
-4,553	3,273	18,132	16,788	-43,748	-60,722	29,127	-8,476	53,800	24,746	19,059	32,137	41,473	-9,810	1,493	-28,375	-21,149	-1,031	-24,698	-
256,902	257,320	238,627	202,244	162,893	197,337	174,695	173,249	169,100	173,764	149,357	128,377	16,858	81,488	86,395	86,940	79,118	75,494	70,209	70,532
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3.2%
65.3%	67.6%	63.9%	62.1%	54.0%	64.3%	53.2%	52.6%	49.1%	48.7%	44.6%	41.1%	11.1%	28.5%	25.7%	24.2%	22.5%	18.9%	17.5%	16.7%
2.85	3.02	2.76	2.49	2.10	2.53	1.85	1.94	1.83	1.91	1.76	1.65	1.06	1.35	1.34	1.36	1.30	1.26	1.25	1.25
2.17	2.34	2.14	1.93	1.56	1.95	1.55	1.58	1.40	1.52	1.35	1.26	0.77	0.98	1.00	0.99	1.01	1.01	0.99	1.02
0.53	0.48	0.57	0.61	0.85	0.56	0.88	0.90	1.04	1.05	1.24	1.43	8.02	2.51	2.89	3.13	3.45	4.28	4.72	4.97
-1.9%	7.2%	13.6%	28.2%	29.3%	19.6%	12.1%	4.6%	7.3%	12.5%	13.2%	23.2%	43.4%	1.6%	1.2%	-2.7%	7.1%	4.6%	2.5%	17.6%
-1.3%	4.9%	8.7%	17.5%	15.8%	12.6%	6.4%	2.4%	3.6%	6.1%	5.9%	9.6%	4.8%	0.5%	0.3%	-0.7%	1.6%	0.9%	0.4%	3.0%
1.01	7.54	11.85	25.55	29.74	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	22 days
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	85 days

EBIT margin: not included in this filing.

A Belgian filing has no cash-flow statement. Cash flow is therefore an approximation, derived from the income statement. Investment is the acquisitions in the notes and, without them, the balance-sheet move.

Social balance sheet

Item	31-12-2025	31-12-2024	31-12-2023	31-12-2022	31-12-2021
Employees at the balance-sheet date	3	3	3	2	2
full-time	-	-	-	-	1
part-time	3	3	3	2	1
in full-time equivalents	1.5	1.5	1.5	0.7	1.3
	1.5	1.4	1.5	1.4	1.3
On a permanent contract	3	2	2	1	2
Joined	-	1	1	1	-
Left	-	1	0	1	-

Source: social balance sheet in the 2021 to 2025 annual accounts

Investments

fixed assets acquired

Item	2025	2024	2023	2022	2021
Tangible fixed assets	-	€4,481	-	€17,680	€2,126
	€4,581	€7,981	€8,142	€8,338	€25,368

Source: notes to the 2021 to 2025 annual accounts (statement of fixed assets)

Insights on OFFIPHARMA

The operating result for 2025 is 99% lower than in 2024 and the lowest since 2006. It is the third fall in a row.

Debt's share of the balance-sheet total rises from 32.4% to 34.7%. Equity is lower and debt is higher.

Board & ownership

Board

1 director, last change in 2021

Director (not named in the articles)

since 13-04-2021 term without a fixed end

earlier manager, until 15-04-2021

listed in the 2025 annual accounts, filed on 31-08-2026

Office holders in the KBO →

Mandates through the years

1 name, the dashed line is today

Director (not named in the articles)

BoardEarliermandate already running before its first mention

Mandates as a list

- Director (not named in the articles), from 13-04-2021 to date
- Manager, until 15-04-2021

See the board, name and registered office on a given date →

Control

See the annual accounts at the National Bank and the publications in the Belgian Official Gazette.

Capital

Contribution: €18,600
Source: 2025 annual accounts

Articles of association

deed of 15-04-2021 (in French)

Duration: Unlimited
Transfer restriction: “Moitié cédant moitié acquéreurs proportionnellement si plusieurs, nullité”
Annual meeting: Fourth Saturday of May at 20:00

Capital transactions

Capital over time

15-04-2021 Converted to unavailable equity · €92,460
15-04-2021 Capital reduction of €72,000 · to €20,460 · repaid to the shareholders

Network & group

No group

OFFIPHARMA has no parent and no holdings in its annual accounts. is the only director. OFFIPHARMA shares no director with another company.

Timeline

32 events since 2004

Board

Capital

Filings

Financial

Establishments

200420062008201020122014201620182020202220242026

Deadline for the 2026 accounts: 31-07-2027

2026

31-08-2026

Annual accounts 2025 filed NBBabbreviated format · 31 days late

2025

31-12-2025

Weakest financial year net -€4,999 The net result drops to -€4,999, the lowest from 2006 to 2025.

09-12-2025

Registered in the Peppol Directory Reachable for e-invoices through 0208:0864276532

18-07-2025

Annual accounts 2024 filed PDFfull format · 13 days before the deadline

2024

19-07-2024

Annual accounts 2023 filed PDFfull format · 12 days before the deadline

2023

20-07-2023

Annual accounts 2022 filed PDFfull format · 11 days before the deadline

2022

31-12-2022

Highest result from 2006 to 2025 net €62,694 ▲23% The operating result of €89,140 and the net result of €62,694 are both a record.

07-07-2022

Annual accounts 2021 filed PDFfull format · 24 days before the deadline

2021

12-07-2021

Annual accounts 2020 filed PDFfull format · 19 days before the deadline

15-04-2021

Capital decrease of €72,000 to €20,460Capital from €92,460 to €20,460, 720 shares cancelled · Change of role: , from manager to director · Legal-form conversion: from private limited company (pre-2019) to private limited company · General meeting of 13-04-20217 points ▸

General meeting, 13-04-2021
Legal-form conversion, from private limited company (pre-2019) to private limited company
Capital decrease, €72,000
186 shares
Director resignation, (manager)
Director appointment, (director (not named in the articles))
Registered office clause, rue du Gouty, n°22 à 6440 FROIDCHAPELLE
The deed holds 8 more points.

Open the deed in the Belgian Official Gazette

2020

14-08-2020

Annual accounts 2019 filed PDFfull format · 14 days late

2019

26-08-2019

Annual accounts 2018 filed PDFfull format · 26 days late

2018

31-12-2018

Equity above €200,000 equity €205,140 ▲4.8% After 8 profitable years in a row, equity reaches €205,140.

24-08-2018

Annual accounts 2017 filed PDFfull format · 24 days late

2017

22-08-2017

Annual accounts 2016 filed PDFfull format · 22 days late

2016

08-08-2016

Annual accounts 2015 filed PDFfull format · 8 days late

2015

31-12-2015

Equity above €150,000 equity €158,731 ▲15.2% After 5 profitable years in a row, equity reaches €158,731.

20-08-2015

Annual accounts 2014 filed PDFfull format · 20 days late

2014

29-08-2014

Annual accounts 2013 filed PDFfull format · 29 days late

2013

01-08-2013

Annual accounts 2012 filed PDFfull format · 1 day late

2012

19-06-2012

Annual accounts 2011 filed PDFfull format · 42 days before the deadline

2011

31-12-2011

Back to profit net €1,255 The net result is €1,255, after one loss-making year.

25-07-2011

Annual accounts 2010 filed PDFfull format · 6 days before the deadline

2010

25-06-2010

Annual accounts 2009 filed PDFfull format · 36 days before the deadline

2009

22-07-2009

Annual accounts 2008 filed PDFfull format · 9 days before the deadline

2008

31-12-2008

Equity above €100,000 equity €100,867 ▲4.8% With a profit in every financial year since 2006, equity grows to €100,867.

22-07-2008

Annual accounts 2007 filed PDFfull format · 9 days before the deadline

2007

06-07-2007

Annual accounts 2006 filed PDFfull format · 25 days before the deadline

2006

06-07-2006

Annual accounts 2005 filed PDFfull format

2005

11-07-2005

Annual accounts 2004 filed PDFfull format

2004

24-03-2004

Incorporation PDFpublished on 09-04-2004

24-03-2004

First establishment Rue du Gouty 22, Froidchapelle

Financial milestones sit on the financial year-end date, not the filing date.

Sources: Publications in the Belgian Official Gazette Filings with the National Bank

History

OFFIPHARMA was incorporated on 24 March 2004.¹ Total assets went from €390,068 in 2018 to €399,757 in 2025 and headcount from 1.5 to 1.5 full-time equivalents.²

Company details

Identity

Enterprise number: 0864.276.532
VAT number: BE 0864.276.532
Peppol ID: 0208:0864276532
Other Peppol ID: 9925:BE0864276532
Legal form: Private limited company
Status: Active, normal situation
Founded: 24-03-2004
Financial year: ends on 31 December
Annual meeting: Fourth Saturday of May at 20:00
deed of 15-04-2021 (in French)
Peppol: Reachable since 09-12-2025Follow this company and you will hear the next morning if it leaves the Peppol register.
Name: OFFIPHARMA in French
Entity type: Legal entity
Duration: Unlimited
deed of 15-04-2021 (in French)

Activities

NACEBEL 2025

VAT activities

47730 Retail sale of pharmaceutical products main activity

Social security (RSZ) activities

47730 Retail sale of pharmaceutical products main activity

Joint committees annual accounts 2025

JC 313 Pharmacies and pricing offices

Codes under NACEBEL 2008

VAT activities

47730 Retail trade main activity

Social security (RSZ) activities

47730 Retail trade main activity

Codes under NACEBEL 2003

VAT activities

52310 main activity

Social security (RSZ) activities

52310 main activity

Purpose: “L’acquisition,la création et l’exploitation d’une ou plusieurs officines; La fabrication et le commerce de tous produits de pharmacie,de…”
6 activities
L’acquisition,la création et l’exploitation d’une ou plusieurs officines
La fabrication et le commerce de tous produits de pharmacie,de biothérapie,de diététique et de soins de santé
L’achat et la vente de matières premières
L’exécution de toutes prescriptions médicales s’y rapportant
Le commerce de tous produits homéopathiques,bandagisterie,ainsi que les accessoires médicaux et d’optique
Toutes opérations relatives à l’achat,la vente,la location ou la gestion,tant pour son compte que pour le compte de tiers,d’immeubles meublés ou non
deed of 15-04-2021 (in French)

Registered office and establishments

1 establishment

Establishment	Since	Unit number	FASFC approval
Rue du Gouty 22 registered office 6440 Froidchapelle	24-03-2004	2.136.141.621	Pharmacy (food >3 months)

Buildings and parcels at the address

Ground area: 1,983 m²
Buildings: 114 m²
Volume, LiDAR: 1,003 m³
Tallest building: 10.4 m

Buildings to scale, each on its own parcel

registered office establishment The establishment unit on the map

Parcels

Cadastral parcel	Area	Buildings	Height / floors
56029C0313/00K000	1,983 m²	1 · 114 m²	10.3 m · 3

Recognitions

Food safety, FASFC

1 site

Froidchapelleunit number 2.136.141.621

1 permission

Pharmacy (food >3 months) · since 17-01-2008

Source: FAVV-AFSCA, open data, updated on 02-11-2026

Overview

Lifetime

Key points

Turnover

Filings

Checked score

Score breakdown

Comparable companies, two years later

Credit verdict

Signals

Board and ownership

Recent changes

Comparable companies

Official details

Annual accounts 2025

Insights on OFFIPHARMA

Financials

Annual accounts 2025

Money flows

Balance sheet

Change in equityin euro

Change in cashin euro

Position in the sector

Solvency65.3%

Current ratio2.85

Return on assets-1.3%

Staff

Staff cost per FTE€78,940

Joined and left

Filed annual accounts

Filings

Key figures and ratios

Social balance sheet

Investments

Insights on OFFIPHARMA

Board & ownership

Board

Mandates through the years

Control

Capital

Articles of association

Capital transactions

Network & group

No group

Timeline

Timeline

History

Company details

Identity

Activities

Registered office and establishments

Buildings and parcels at the address

Location

Parcels

Recognitions

Food safety, FASFC

in euro

in euro

65.3%

2.85

-1.3%

€78,940